Last updated on March 2019

A Phase 1 Multi-Center Open-Label Dose-Escalation Safety Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors


Brief description of study

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of MinnelideCapsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors

Clinical Study Identifier: NCT03129139

Contact Investigators or Research Sites near you

Start Over

Mayo Clinic Arizona

Phoenix, AZ United States
  Connect »

HonorHealth Research Institute

Scottsdale, AZ United States
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

Mayo Clinic

Jacksonville, FL United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.